stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) EV/Sales
As of 5 November 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a EV/Sales of 66.6×. Over the past ten years it has ranged from 0.0× (December 2023) to 552× (July 2026); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 156× | 347.61% |
| FY2024 | 34.9× | 23.60% |
| FY2023 | 28.2× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 91.9× | (81.54%) |
| Jun 2026 | 498× | 244.80% |
| Mar 2026 | 144× | (7.59%) |
| Dec 2025 | 156× | 105.50% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHVS Pharvaris N.V. compare | n/m |
| MBX MBX Biosciences, Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| ADMA ADMA Biologics Inc compare | 5.8× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 19.8× |
| XNCR Xencor, Inc. compare | 21.6× |
| PVLA Palvella Therapeutics, Inc. compare | 48.1× |
| NAMS NewAmsterdam Pharma Company N.V. | 66.6× |
| CLDX Celldex Therapeutics, Inc. compare | 1,691× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement